Current Study
PROPEL-IPF
This clinical trial is evaluating an investigational oral medication to determine whether it is safe, well tolerated, and effective in people with IPF. Participants in this Phase 2 study will be randomly assigned (by chance) to receive one of two different doses of said medication or a placebo. The placebo looks the same as the study medication but does not contain any active ingredients. Neither participants nor study doctors will know which treatment is being given. The treatment period lasts approximately 26 weeks, with total participation of up to 36 weeks, including screening and follow-up. During this time, participants will attend clinic visits and be regularly monitored by the study team to assess lung function, symptoms, and overall health.
Study Status
Recruiting
Duration
up to 36 weeks
Clinic Visits
11
Phone Check-ins
0
Study Overview
Location
Spearwood
Phase
2
Study Duration
up to 36 weeks
Main Entry Criteria
- Are an adult diagnosed with idiopathic pulmonary fibrosis (IPF)
- Have a confirmed diagnosis of IPF made by a specialist
- May be receiving standard IPF treatment, or not currently on treatment
- Are willing to take a daily oral study medication for the duration of the study
- Are able to attend scheduled clinic visits and complete study assessments
Main Exclusion Criteria
- Have a lung condition other than IPF that could affect study results
- Have any significant or unstable medical condition that may make participation unsafe (as determined by the study doctor)
- Have recently taken part in another clinical trial or received investigational treatment
- Have had a recent serious illness or medical event that could interfere with the study
Assessments
- ECG
- Blood pressure and pulse
- Physical examinations
- Questionnaires
- Breathing tests
- Blood and urine tests
- CT scans
At a Glance
Clinic Visits
11
Phone Calls
0
Duration
up to 36 weeks